JointHealth™ express May 9, 2011
Your Voice is Important
Were you aware that in British Columbia you can provide input to the Ministry of Health about specific medications it is reviewing through a website called Your Voice? Through this website, patients, caregivers, and patient advocacy groups can add their voices to the BC PharmaCare drug review process.
The input is reviewed by the Drug Benefit Council, which then gives recommendations on whether a medication should be covered, and how, by PharmaCare. PharmaCare then makes a decision based on those recommendations and available resources. Policies and plans already in place also factor in the decision making process.
Currently on the Your Voice website, people can provide their feedback about denosumab (Prolia®). Denosumab is used for the treatment of osteoporosis in postmenopausal women at high risk for bone fracture. If you are eligible, that is, you have osteoporosis, or you are a caregiver to someone who has osteoporosis, or your organization represents patients with this disease, then you can provide input for consideration by the Drug Benefit Council by filling out an online questionnaire or a printable version that you mail in.
It is an opportunity for you to share your perspectives on medication decisions that affect you.
At the following links you will find details about denosumab and when you scroll to the bottom of the page, you will find the questionnaire.
For patients: click here
For caregivers: click here
For patient advocacy groups: click here. (Advocacy groups are required to register their name with the Ministry of Health before making their submission.)
The deadline for submitting input on denosumab is midnight on May 20, 2011.
Sincerely,
Arthritis Consumer Experts
www.jointhealth.org
Your Voice is Important
Were you aware that in British Columbia you can provide input to the Ministry of Health about specific medications it is reviewing through a website called Your Voice? Through this website, patients, caregivers, and patient advocacy groups can add their voices to the BC PharmaCare drug review process.
The input is reviewed by the Drug Benefit Council, which then gives recommendations on whether a medication should be covered, and how, by PharmaCare. PharmaCare then makes a decision based on those recommendations and available resources. Policies and plans already in place also factor in the decision making process.
Currently on the Your Voice website, people can provide their feedback about denosumab (Prolia®). Denosumab is used for the treatment of osteoporosis in postmenopausal women at high risk for bone fracture. If you are eligible, that is, you have osteoporosis, or you are a caregiver to someone who has osteoporosis, or your organization represents patients with this disease, then you can provide input for consideration by the Drug Benefit Council by filling out an online questionnaire or a printable version that you mail in.
It is an opportunity for you to share your perspectives on medication decisions that affect you.
At the following links you will find details about denosumab and when you scroll to the bottom of the page, you will find the questionnaire.
For patients: click here
For caregivers: click here
For patient advocacy groups: click here. (Advocacy groups are required to register their name with the Ministry of Health before making their submission.)
The deadline for submitting input on denosumab is midnight on May 20, 2011.
Sincerely,
Arthritis Consumer Experts
www.jointhealth.org
Arthritis Consumer Experts
ACE thanks Arthritis Research Canada (ARC) for its scientific review of ACE and JointHealth™ information and education programs.